


# Designing novel biologic agents to target colorectal cancer

August 29 2017



Credit: Mary Ann Liebert, Inc., publishers

New biologic drugs, such as monoclonal antibodies and immunotherapies in clinical development, designed to target metastatic colorectal cancer (CRC) and stimulate the immune system to destroy tumor cells are a significant advance in treatment over conventional chemotherapy. A comprehensive overview of novel approaches to combating CRC, the fourth most common type of tumor worldwide that has already metastasized when diagnosed in more than 50% of patients, is presented in *Cancer Biotherapy and Radiopharmaceuticals*.

In the article entitled "Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives," Fang Geng, Zheng Wang, Hang Yin, Junxian Yu, and Banwei Cao, Beijing Friendship Hospital, Capital Medical University, Beijing, China, provide insights into the new biological agents approved by the U.S. Food and Drug Administration for metastatic CRC and their ability to extend patients' medical overall survival. The authors also present a detailed examination of investigational drugs currently in clinical trials, including immunotherapeutic agents such as [monoclonal antibodies](#) targeting PD-1/PD-L1, which have been approved to treat other types of cancer. The discussion on future directions and prospects for novel therapeutic strategies includes topics such as the promise of combination therapies, and approaches to overcoming [drug](#) resistance.

"This review highlights the significant progress that is being made with targeted biological agents alone, and in combination with chemotherapy, for the treatment of [metastatic colorectal cancer](#), including the use of immunotherapy. It is a valuable resource for current research in this area," says *Cancer Biotherapy and Radiopharmaceuticals* Co-Editor-in-Chief Donald J. Buchsbaum, PhD, Department of Radiation Oncology, Division of Radiation Biology, University of Alabama at Birmingham.

**More information:** Fang Geng et al, Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future

Perspectives, *Cancer Biotherapy and Radiopharmaceuticals* (2017). [DOI: 10.1089/cbr.2017.2210](https://doi.org/10.1089/cbr.2017.2210)

Provided by Mary Ann Liebert, Inc

Citation: Designing novel biologic agents to target colorectal cancer (2017, August 29) retrieved 16 June 2024 from <https://medicalxpress.com/news/2017-08-biologic-agents-colorectal-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.